Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 10, 2024

The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

Episodes in this series

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 9 Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 10 Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"

EP. 11 The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"

EP. 12 Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 13 Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man having heart attack - dragonstock - stock.adobe.com

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

ByPearl Steinzor

July 22nd 2026

David Zhang

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 22nd 2026

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

ByBrooke McCormick

July 22nd 2026

David Zhang

Real-World PRS Data Advance IPF Risk Prediction, Diagnosis: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 21st 2026

mantle cell lymphoma | Image: Perla Vicari / ASH Image Bank

Case Studies Focus on Glofitamab as Bridge to CAR T in MCL

July 20th 2026

Trending on AJMC

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

When the Oncologist Becomes the PCP: Emily K. Curran, MD

Geographical Access to Preferred Pharmacies in Medicare Part D